TY - JOUR
T1 - Effect of low-dose theophylline on airway inflammation in COPD
AU - Kobayashi, Motoko
AU - Nasuhara, Yasuyuki
AU - Betsuyaku, Tomoko
AU - Shibuya, Eiji
AU - Tanino, Yoshinori
AU - Tanino, Mishie
AU - Takamura, Kei
AU - Nagai, Katsura
AU - Hosokawa, Takeshi
AU - Nishimura, Masaharu
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2004/6
Y1 - 2004/6
N2 - Objective: Recent studies have shown that theophylline may exert anti-inflammatory effects on neutrophils. We undertook to assess the effect of theophylline on airway inflammation in COPD. Methodology: We performed a 4-week randomized double-blind, placebo-controlled study in 11 theophylline-naive patients with mild to moderate COPD. After a 1-week run-in period, six subjects were administered 400 mg/day theophylline (Theodur; Nikken Chemicals Co. Ltd, Tokyo, Japan) for 4 weeks, while five subjects were administered a placebo. Induced sputum was obtained before and after the run-in period and then after 2 and 4 weeks of treatment. Cell differential count and levels of interleukin-8, matrix metalloproteinase-9, neutrophil elastase (NE), myeloperoxidase (MPO), α1-antitrypsin (αs1-AT), leukotriene B 4 and tissue inhibitor of metalloproteinases-1 (TIMP-1) were assessed. Results: No variable was significantly different during the run-in period or with placebo treatment. In contrast, theophylline treatment significantly decreased NE and MPO levels at 4 weeks, although the cell differential count did not change appreciably as a result of treatment. Conclusion: These results suggest that 4 weeks of theophylline treatment attenuates neutrophil-associated inflammation in the airways of mild to moderate COPD patients. However, the clinical benefits remain to be determined.
AB - Objective: Recent studies have shown that theophylline may exert anti-inflammatory effects on neutrophils. We undertook to assess the effect of theophylline on airway inflammation in COPD. Methodology: We performed a 4-week randomized double-blind, placebo-controlled study in 11 theophylline-naive patients with mild to moderate COPD. After a 1-week run-in period, six subjects were administered 400 mg/day theophylline (Theodur; Nikken Chemicals Co. Ltd, Tokyo, Japan) for 4 weeks, while five subjects were administered a placebo. Induced sputum was obtained before and after the run-in period and then after 2 and 4 weeks of treatment. Cell differential count and levels of interleukin-8, matrix metalloproteinase-9, neutrophil elastase (NE), myeloperoxidase (MPO), α1-antitrypsin (αs1-AT), leukotriene B 4 and tissue inhibitor of metalloproteinases-1 (TIMP-1) were assessed. Results: No variable was significantly different during the run-in period or with placebo treatment. In contrast, theophylline treatment significantly decreased NE and MPO levels at 4 weeks, although the cell differential count did not change appreciably as a result of treatment. Conclusion: These results suggest that 4 weeks of theophylline treatment attenuates neutrophil-associated inflammation in the airways of mild to moderate COPD patients. However, the clinical benefits remain to be determined.
KW - Airway inflammation
KW - COPD
KW - Induced sputum
KW - Neutrophils
KW - Theophylline
UR - http://www.scopus.com/inward/record.url?scp=3142744558&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3142744558&partnerID=8YFLogxK
U2 - 10.1111/j.1440-1843.2004.00573.x
DO - 10.1111/j.1440-1843.2004.00573.x
M3 - Article
C2 - 15182277
AN - SCOPUS:3142744558
VL - 9
SP - 249
EP - 254
JO - Respirology
JF - Respirology
SN - 1323-7799
IS - 2
ER -